Endpoints 11 winner 2025: Averna Therapeutics wants to harness jumping genes
When Roy Amariglio ...
View ArticleEndpoints 11 winner 2025: Judo Bio broadens the reach of RNA drugs
Key leaders CEO Rajiv Patni, CSO Alfica Sehgal; Founder Steven Robinette, Co-Founders Chelsea Place Johnson and Andrew Fraley Total raised $100M Headquarters Cambridge, MA Key Investors Atlas, TCG,...
View ArticleEndpoints 11 winner 2025: Stylus Medicine wants to bring CAR-T to the masses
Key leaders CEO Emile Nuwaysir, CSO Jason Fontenot; Scientific co-founders Ami Bhatt, Patrick Hsu, Michael Bassik and Lacramioara Bintu Total raised $85M Headquarters Cambridge, MA Key investors RA...
View ArticleEndpoints 11 winner 2025: Sironax swings big in neurology as China biotech rises
Fifteen years ago, one of China’s top scientists, Xiaodong ...
View ArticleEndpoints 11 winner 2025: Dispatch Bio's ambitious plans for solid tumor cell...
When Carl June, Bob Nelsen and ...
View ArticleEndpoints 11 winner 2025: Orbis Medicines uses macrocycles to make a...
In drug development, most treatments typically ...
View ArticleEndpoints 11 winner 2025: Third Arc's talented team goes after big targets
Some biotechs stand out because of their novel scientific promise ...
View ArticleEndpoints 11 winner 2025: Candid Therapeutics builds the next autoimmune...
If you could package many of the ...
View ArticleEndpoints 11 winner 2025: Umoja Biopharma hopes to break CAR-T's in vivo barrier
In vivo CAR-T is having a moment. In the space of six months, several ...
View ArticleThe 2025 winners of the Endpoints 11: Biotech's most exciting startups
Can superintelligent AI build a pipeline at the frontier of science? Can developers finally break down the barriers to treating solid tumors with in vivo CAR-T? Can the inherent promise of oncolytics...
View ArticleEndpoints 11 winner 2025: Chai Discovery aims to design drugs on the computer
Joshua Meier found his way onto Zavain ...
View ArticleCDC vaccine advisors shelve vote on hepatitis B birth dose
The CDC’s Advisory Committee on Immunization Practices decided on Friday to postpone a vote on the hepatitis B vaccine for newborns, a surprising turn of events after the panel appeared positioned to...
View ArticleCHMP recommends Novo's weekly diabetes injection, Bayer's menopause drug
The European Medicines Agency’s human medicines committee (CHMP) has recommended the approval of Novo Nordisk’s weekly diabetes injection that combines its insulin icodec and the GLP-1 drug...
View ArticleRegeneron’s Lynozyfic yields 100% response rate in small smoldering multiple...
Regeneron reported efficacious early results on its T cell engager Lynozyfic in smoldering multiple myeloma, a precancerous condition that can turn into active multiple myeloma. The study is part of a...
View ArticleMerck wins approval of subcutaneous Keytruda, in bid to extend life of...
The FDA on Friday approved a new, subcutaneous formulation of the cancer drug Keytruda, which is expected to help Merck stave off some biosimilar competition in the years to ...
View ArticleACIP recommends that people consult a provider before getting Covid shots
The CDC’s panel of vaccine advisors voted Friday to recommend that all people 6 months and older receive consultation from a healthcare provider before getting a Covid-19 shot. The Advisory Committee...
View ArticleMapLight prepares for IPO to back schizophrenia, Alzheimer's drug
MapLight Therapeutics filed for an initial public offering on Friday evening, a week after a biotech that's also working on schizophrenia treatments, LB Pharmaceuticals, notched the industry's
View ArticleThis year’s Endpoints 11 winners; Monarez testifies to Congress; Eli Lilly’s...
Welcome back to Endpoints Weekly! This week, our team gathered in Boston to honor 11 of the most promising biotech startups of 2025. Be sure to check out this year’s list of companies chasing bold ...
View ArticleRoche declares Phase 3 win for SERD in broad breast cancer population that...
Roche’s estrogen receptor-targeting pill beat standard of care in a Phase 3 breast cancer trial, the company said Monday. However, one key question remains: Out of all the patients in the ...
View ArticlePfizer goes full speed ahead on obesity with $4.9B acquisition of Metsera
After looking like a down-and-out player in obesity, Pfizer is making the flashiest acquisition yet by a large pharma in the weight loss field. On Monday, Pfizer announced it would buy ...
View Article